2 news items
GlycoMimetics Announces Results of Pivotal Phase 3 Study of Uproleselan in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)
GLYC
6 May 24
in 2023. These increases were due to raw material acquisition costs for future manufacturing batches
GlycoMimetics Reports Highlights and Financial Results for Fourth Quarter and Full Year 2023
GLYC
27 Mar 24
and impact of the company's drug candidates. Actual results may differ materially from those described in these forward-looking statements. For a further
- Prev
- 1
- Next